Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
R Polo, X García-Albéniz, C Terán, M Morales, D Rial-Crestelo, MA Garcinuño, M García del Toro, C Hita, JL Gómez-Sirvent, L Buzón, A Díaz de Santiago, JL Pérez Arellano, J Sanz, P Bachiller, E Martínez Alfaro, V Díaz-Brito, M Masiá, A Hernández-Torres, J Guerra, J Santos, P Arazo, L Muñoz, JR Arribas, P Martínez de Salazar, S Moreno, MA Hernán, J Del Amo EPICOS
doi: https://doi.org/10.1101/2022.03.02.22271710
R Polo
1Division for HIV, STI, Viral Hepatitis and TB Control. Ministry of Health, Madrid, Spain
X García-Albéniz
2CAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
3RTI Health Solutions, Barcelona, Spain
C Terán
4Facultad de Medicina Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca - Hospital Santa Bárbara, Sucre, Bolivia
M Morales
5Hospital Militar Dr. Carlos Arvelo, Caracas, Venezuela
D Rial-Crestelo
6Hospital Doce de Octubre, Madrid, Spain
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
MA Garcinuño
8Hospital Nuestra Señora de Sonsoles, Ávila, Spain
M García del Toro
9Hospital General de Valencia, Spain
C Hita
10Hospital de Torrejón, Madrid, Spain
JL Gómez-Sirvent
11Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
L Buzón
12Hospital Universitario de Burgos, Burgos, Spain
A Díaz de Santiago
13Hospital Universitario Puerta de Hierro, Madrid, Spain
JL Pérez Arellano
14Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain
J Sanz
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
15Hospital Universitario de la Princesa, Madrid, Spain
P Bachiller
16Hospital General de Segovia. Segovia, Spain
E Martínez Alfaro
17Complejo Hospitalario Universitario de Albacete, Albacete, Spain
V Díaz-Brito
18Parc Sanitari Sant Joan de Déu, Barcelona, Spain
M Masiá
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
19Hospital General Universitario de Elche, Alicante, Spain
A Hernández-Torres
20Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
J Guerra
21Hospital Universitario de León, León, Spain
J Santos
22Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain
P Arazo
23Hospital Universitario Miguel Servet. Zaragoza, Spain
L Muñoz
24Complejo Hospitalario Universitario de Granada, Granada, Spain
JR Arribas
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
25Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
P Martínez de Salazar
26Center for Communicable Disease Dynamics, Department of Epidemiology. Harvard T.H. Chan School of Public Health, Boston, Massachsetts, USA
S Moreno
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
27Hospital Universitario Ramón y Cajal, Madrid, Spain
MA Hernán
2CAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
28Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
J Del Amo
1Division for HIV, STI, Viral Hepatitis and TB Control. Ministry of Health, Madrid, Spain
7CIBER de Enfermedades Infecciosas. Institute of Health Carlos III, Madrid, Spain
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted March 04, 2022.
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
R Polo, X García-Albéniz, C Terán, M Morales, D Rial-Crestelo, MA Garcinuño, M García del Toro, C Hita, JL Gómez-Sirvent, L Buzón, A Díaz de Santiago, JL Pérez Arellano, J Sanz, P Bachiller, E Martínez Alfaro, V Díaz-Brito, M Masiá, A Hernández-Torres, J Guerra, J Santos, P Arazo, L Muñoz, JR Arribas, P Martínez de Salazar, S Moreno, MA Hernán, J Del Amo
medRxiv 2022.03.02.22271710; doi: https://doi.org/10.1101/2022.03.02.22271710
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
R Polo, X García-Albéniz, C Terán, M Morales, D Rial-Crestelo, MA Garcinuño, M García del Toro, C Hita, JL Gómez-Sirvent, L Buzón, A Díaz de Santiago, JL Pérez Arellano, J Sanz, P Bachiller, E Martínez Alfaro, V Díaz-Brito, M Masiá, A Hernández-Torres, J Guerra, J Santos, P Arazo, L Muñoz, JR Arribas, P Martínez de Salazar, S Moreno, MA Hernán, J Del Amo
medRxiv 2022.03.02.22271710; doi: https://doi.org/10.1101/2022.03.02.22271710
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2154)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)